Hobbyist studying old map notices odd mark that leads to medieval find in Sweden
Göran Bengtsson, a hobby archaeologist, was studying an 18th-century map of southwestern Sweden when he noticed something unusual.
A rectangle and the word 'Klosterkullen,' which translates to 'monastery hill,' was drawn in an area that today is an empty field in Derome, according to a May 13 news release from the Swedish archaeology service Arkeologerna.
On a dry summer day, Bengtsson scanned the area using a drone and metal detector. He found clear traces or crop marks in the ground — evidence of a buried structure, experts said.
Bengtsson enlisted the help of professional archaeologist Bengt Westergaard at Arkeologerna.
Ground-penetrating radar confirmed the presence of 6.5-feet-thick walls, pillar foundations and other building parts.
Bengtsson had discovered a medieval monastery likely dating back to the late 12th century, according to the release.
Experts said this may have been the east wing of the unfinished Cistercian monastery of Ås, the release said.
A letter from a meeting in 1243 shows the then-abbot, or head of the monastery, applied to have it moved. The site was relocated some time during the 13th century, according to experts.
Westergaard said in his 40 years as an archaeologist, he has never seen anything like this, according to the release.
The Order of Cistercians was part of the Roman Catholic monastic order founded in 1098. The group was made up of monks, and eventually, nuns.
Additional ground-penetrating radar scans will be performed to try and locate more of the monastery, experts said. No archaeological excavations have been planned.
Derome is about a 340-mile drive southwest from Stockholm.
Google Translate was used to translate the news release from Arkeologerna.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®
Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with Xbrane Biopharma AB ('Xbrane'), with the acqusition of the R&D organization of Xbrane in Sweden and biosimilar candidate to Cimzia® (certolizumab pegol). All regulatory conditions have been fulfilled. The transaction, which was announced on March 20, 2025, and approved by Xbrane's Extraordinary General Meeting on April 14, 2025, entails a total purchase price of approximately SEK 275 million (US$28,9 million), consisting of: • A cash payment of approximately SEK 102.2 million• Assumption of convertible debt of approximately SEK 152.75 million• Assumption of accounts payable related to the biosimilar candidate of approximately SEK 20 million The acquisition will further expand Alvotech's development capacity and establish a strong presence in the Swedish life science sector. Use of trademarksCimzia® is a registered trademark of UCB Pharma S.A. About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy's (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit None of the information on the Alvotech website shall be deemed part of this press release. For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube. Alvotech Forward Looking StatementsCertain statements in this communication may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech's expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, and market launches. In some cases, you can identify forward-looking statements by terminology such as 'may', 'should', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential', 'aim' or 'continue', or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability to complete development of biosimilar candidates, including the biosimilar candidate to Cimzia; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (5) Alvotech's estimates of expenses and profitability; (6) Alvotech's ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (8) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (10) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (11) the ability of Alvotech's partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (12) Alvotech's ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (13) the success of Alvotech's current and future collaborations, joint ventures, partnerships or licensing arrangements; (14) Alvotech's ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (15) Alvotech's ability to manufacture sufficient commercial supply of its approved products; (16) the outcome of ongoing and future litigation regarding Alvotech's products and product candidates; (17) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, conflicts in Ukraine, the Middle East and other global geopolitical tension, on the Company's business, financial position, strategy and anticipated milestones; and (18) other risks and uncertainties set forth in the sections entitled 'Risk Factors' and 'Cautionary Note Regarding Forward-Looking Statements' in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication. ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONSBenedikt Stefansson,
Yahoo
5 hours ago
- Yahoo
BPC Instruments receives orders from KU Leuven valued at 0.7 MSEK
LUND, Sweden, June 4, 2025 /PRNewswire/ -- BPC Instruments AB (publ) ("BPC") announces orders from KU Leuven university in Belgium. The orders include the delivery of several instruments, including Gas Endeavour® III systems, with a combined value of approximately 0.7 MSEK. CEO Dr. Jing Liu comments: "We are pleased to receive a significant order from a globally recognised research institution. KU Leuven's decision to transition to our technology confirms the value and reliability of our instruments in advanced scientific applications." BPC has received orders from university KU Leuven in Belgium. The value of the orders amounts to approximately 0.7 MSEK and includes several instruments including Gas Endeavour® III. The university is replacing and upgrading its setup for biochemical methane potential (BMP) testing with BPC's instruments for both batch and continuous measurements. The new systems are expected to streamline workflows and provide more precise and reliable data in research related to biological and biochemical gas processes. Revenue from these orders is expected to be recognised in Q2 2025. About Gas Endeavour® III Gas Endeavour® III is an advanced laboratory instrument platform designed for precise evaluation of gas production or consumption measurements in both batch and continuous processes. With its fully automated operation, an intuitive user interface, and high reliability, it offers exceptional ease of use. The system is available with 18 or 9 parallel channels, allowing for the simultaneous evaluation of multiple samples. For more information about Gas Endeavour® III, visit the Gas Endeavour® III product page or contact the sales team at sales@ For more information, please contact: Dr. Jing Liu, CEOBPC Instruments AB Tel: +46 (0) 46 16 39 51 E-mail: ir@ About BPC Instruments AB BPC Instruments is a global Swedish-based pioneering technology company developing and offering analytical instruments enabling more efficient, reliable, and higher quality research and analysis for industries in renewable bioenergy and environmental biotechnology. The result is not only higher accuracy and precision, but also a significant reduction in time consumption and labor requirement for performing analysis. BPC Instruments' innovative products offer high-quality hardware and software based on deep knowledge and experience of target applications. The solutions are the first of their kind, making the company a pioneer in its field. Today, BPC Instruments exports to nearly 80 countries around the world. BPC is listed on the Spotlight Stock Market in Sweden. For more information, please visit BPC's webpage: This information was brought to you by Cision The following files are available for download: Press release - KU Leuven View original content:
Yahoo
a day ago
- Yahoo
A bottlenose dolphin? Or Tursiops truncatus? Why biologists give organisms those strange, unpronounceable names
Most people would call it a 'field mouse,' but a scientist would ask, 'Was it Peromyscus maniculatus? Or Peromyscus leucopus?' Scientists use a system of complicated-sounding names to refer to everyday creatures, a practice heavily lampooned in the Warner Bros. cartoons featuring the Road Runner and Wile E. Coyote – or, respectively, Accelleratii incredibus and Carnivorous vulgaris. As a biologist, I use these seemingly odd names myself and help my students learn them. For most people it's a huge effort, like learning a second language. That's because it is. The science of naming and classifying organisms is called taxonomy. Scientists do this so they can be as precise as possible when discussing living things. The first word in an organism's name is its genus, which is a group of related species, such as Panthera for lions, tigers and leopards. The second word is the specific name identifying the species, usually defined as a population that can reproduce only with each other, such as Panthera leo for lion. Every two-word combination must be unique. Called binomial nomenclature, this naming system was popularized by Swedish naturalist Carl Linnaeus in the 1700s. So, humans are Homo sapiens, the red maple Acer rubrum, garlic Allium sativum, and the eastern spotted skunk Spilogale putorius. Today, biologists maintain huge databases containing the taxonomic names of plants, animals, fungi and other organisms. For instance, one of these databases – the Open Tree of Life project – includes over 2.3 million species. The scientist who discovers a species usually names it by publishing a formal description in a peer-reviewed journal. From there, the name makes its way into the databases. From then on, scientists always use that name for the organism, even if it turns out to be misleading. For example, many fossils were originally given names containing the Greek root 'saur,' which means lizard – even though paleontologists later realized dinosaurs were not lizards. To most people, these names sound inscrutable. Particularly nowadays, as science becomes more open and accessible to everyone, such arcane vocabulary can come across as old-fashioned and elitist. Given the current backlash against 'elites' and 'experts' in every field, that's a serious charge. But in a roundabout way, this seemingly exclusive practice is really a story of inclusiveness. As modern science began taking shape in Europe during the 1600s, scientists had a problem. They wanted to read and be read by others, but language got in the way. French scientists couldn't read Swedish, Swedes couldn't read Italian, and Italians couldn't read German. Also, writing about plants and animals posed a particular challenge: Many species had common names that could vary from place to place, and some common names might apply to multiple species. Scientists needed a way to be precise and consistent when referring to species, so that everyone could understand each other. To sidestep the language issue, scientists of the era mostly published their work in classical Latin. Back then, everyone learned it – at least every European man wealthy enough to attend school and become a scientist. Others published in classical Greek, also widely taught. By sticking with these more universally known languages, early scientists made sure that science was accessible to as many of their peers as possible. By the late 1700s and 1800s, translation services were broadly available, so naturalists such as Georges Cuvier could write in his native French, and Charles Darwin in his native English. Today, English has become the de facto language for science, so most scientists publish in English regardless of their native tongue. So why continue to use Latin and Greek names today? Taxonomists do it partly out of tradition, but partly because the terminology is still useful. Even without seeing a photo of the animal, a biologist might work out that Geomys bursarius – 'earth-mouse with a pouch' – was a pocket gopher. Or that Reithrodontomys fulvescens – 'groove-toothed mouse that is yellow' – is a yellow mouse with grooves on its incisors. Although taxonomists still largely adhere to the naming principles of Linnaeus, new scientific names are more and more frequently derived from non-European languages. For example, a chicken-size dinosaur discovered and named in China is called Yi qi, meaning 'strange wing' in Mandarin. Some of the more recent names are touched by whimsy, with a few honoring politicians and celebrities. Etheostoma obama is a spangled darter named after the 44th U.S. president; the Swift twisted-claw millipede – Nannaria swiftae – is named after pop star Taylor Swift. With so much of Earth's biodiversity yet to be discovered and named, remember that names are just names. What we call these species often reflects our own values and perspectives. In the future, another language – or no language at all – might rise to dominance. Artificial intelligence may act as a universal translator. This possibility would let everyone publish and read science in their own language. Predicting how technology will change our relationship with terminology is challenging, but the need for precise scientific language, including the names of species, will never go away. This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Nicholas Green, Kennesaw State University Read more: How many types of insects are there in the world? Thousands of undiscovered mammal species may be hidden in plain sight, new research finds Scientists discover five new species of black corals living thousands of feet below the ocean surface near the Great Barrier Reef Nicholas Green does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
